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OBJECTIVES: Orthotopic liver transplantation has improved survival in patients with end-stage liver disease;
however, therapeutic strategies that achieve ideal immunosuppression and avoid early complications are lacking.
To correlate the dose and level of Tacrolimus with early complications, e.g., rejection, infection and renal
impairment, after liver transplantation. From November 2011 to May 2013, 44 adult liver transplant recipients
were studied in this retrospective comparative study.
RESULTS: The most frequent indication for liver transplantation was hepatitis C cirrhosis (47.7%), with a higher
prevalence observed in male patients (68.18%). The ages of the subjects ranged from 19-71 and the median age
was 55.5 years. The mean length of the hospital stay was 16.1¡9.32 days and themeanModel for End-stage Liver
Disease score was 26.18¡4.28. There were five cases of acute cellular rejection (11.37%) and 16 cases of infection
(36.37%). The blood samples that were collected and analyzed over time showed a significant correlation
between the Tacrolimus blood level and the deterioration of glomerular filtration rate and serum creatinine
(p,0.05). Patients with infections had a higher serum level of Tacrolimus (p=0.012). The dose and presence of
rejection were significantly different (p=0.048) and the mean glomerular filtration rate was impaired in patients
who underwent rejection compared with patients who did not undergo rejection (p=0.0084).
CONCLUSION: Blood Tacrolimus levels greater than 10 ng/ml were correlated with impaired renal function. Doses
greater than 0.15 mg/kg/day were associated with the prevention of acute cellular rejection but predisposed
patients to infectious disease.
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& INTRODUCTION
Orthotopic liver transplantation (OLT) has markedly
improved survival in patients with end-stage liver disease,
especially due to advances in surgical techniques, anesthesia
and immunosuppressive therapy. Calcineurin inhibitors
(CNIs) (1-3) have dramatically improved patient survival
after OLT; however, nephrotoxicity, renal dysfunction with
chronic renal injury and end-stage kidney disease occur in
3-20% of recipients taking CNIs post-transplant and these
conditions contribute to the high morbidity and mortality
associated with this course (2-4). Thus, CNI therapy must be
closely monitored. Furthermore, the development of ther-
apeutic strategies that achieve effective immunosuppression
while limiting early complications, such as infection, rejection
or renal failure, remains a real challenge after OLT (5,6).
The purpose of this study was to determine the relation-
ship between the dose and blood level of Tacrolimus with
early complications post-OLT.
& MATERIALS AND METHODS
Study design
We analyzed 44 adult OLT recipient patients in the Liver
GI Transplant Division within the Department of Gastroen-
terology, University of Sa˜o Paulo School of Medicine during
the first 30 post-operative days, from November 2011 to May
2013. We retrospectively studied their demographic, clinical
and laboratory data. Rejection episodes were biopsied and
defined by the Banff criteria (7). Complications from bacterial,
fungi or viral infections at any site were determined. Blood
samples were collected daily during hospitalization and at
least weekly during the first month after OLT to analyze the
creatinine level and glomerular filtration rate (GFR). GFR was
estimated according to the Cockcroft-Gault equation (8).
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Inclusion and exclusion criteria
The following parameters were excluded from analysis:
living donor recipients, severe acute hepatitis, combined
liver-kidney transplantation, split liver, use of immunosup-
pressants other than Tacrolimus and prednisone, very ill
patients (MELD.40) and those who died before the 30-day
follow-up. These patients exhibited multifactorial variables
and no linear use of immunosuppression. Demographic
parameters were evaluated in these patients. The mean,
standard deviation, median, range, number and percentage
were calculated for each parameter. The graphics were
analyzed over time and compared with the blood level and
dose of Tacrolimus, GFR and serum creatinine.
Immunosuppression regime, diagnostic criteria and
group definitions
In all cases, transplants were performed via the piggyback
technique (9). The preservation solutions most commonly
used were ViaspanH and CustodiolH. These immunosup-
pressive regimens followed a general protocol, but each was
customized as necessary. All patients received a steroid (ST)
bolus during the anhepatic phase (500 mg), which was
decreased to 20 mg/day and tapered to a complete stop
within 3 to 6 months of transplantation. Tacrolimus was
orally administered and maintained in all patients (0.10-
0.15 mg/kg/day administered via two daily doses admi-
nistered every 12 hours). All patients with acute cellular
rejection (n = 5) were included in the rejection group with
established evidence in laboratory analysis, histological
findings (Banff criteria) and the treatment used. Episodes
of infection were confirmed in patients (n = 16) by positive
cultures from any site and laboratory abnormalities (leuko-
cytosis and increased C-reactive protein).
Statistical analysis
Results are expressed using descriptive measures (means
¡ standard error) for the following variables: Tacrolimus
dose (mg/kg/day), serum level of Tacrolimus (ng/ml) and
GFR (ml/min). The Student t-test and Mann-Whitney test
were used to compare quantitative and categorical vari-
ables, respectively, among groups. These variables were
compared between groups with and without occurrence of
infection or between groups with or without rejection by
analysis of variance (ANOVA) with repeated measures
using a nonparametric statistical program in R (Version
2.15.1). Differences were considered statistically significant
when p,0.05.
Ethical aspects
The study was approved by the Ethics Committee of
Human Experimentation.
& RESULTS
Clinical and Demographic Population Profile
We observed a higher prevalence of male gender (68.18%)
compared with female gender. The mean age of the patients
was 52.43 years old (¡12.33); the median age was 55.5 years
old and the range was 19-71 years old. The mean weight was
75.15 kg (¡18.61); the mean of body max index (BMI) was
25.94¡4.58 and the mean length of hospital stay was 16.1¡9.32
days. The major cause for transplantation was hepatitis C
virus-induced cirrhosis (47.7%), followed by alcoholic cirrhosis
(13.6%), primary sclerosing cholangitis (6.8%), cryptogenic
cirrhosis (6.8%), autoimmune hepatitis (6.8%), hepatitis B virus
cirrhosis (6.8%), nonalcoholic fatty liver disease (4.7%) and
other (6.8%). The mean MELD score was 26.18¡4.28 (Table 1).
Overall patient characteristics
The patients were evaluated over time (3, 5, 7, 10 and 15
days post-transplant) and then divided into groups based on
the presence or absence of infection or rejection. The number
and percentage of patients in each group are as follows:
infection (n = 16/36.37%), no infection (n = 28/63.63%), rejec-
tion (n = 5/11.37%) and no rejection (n = 39/88.64%) (Table 2).
We observed that the mean age of patients with rejection was
lower than that of the other groups and the weight of this
group was higher than that of the other groups. The mean
hospital stay was longer in patients with infection than in
those without infection (p= 0.003) and those with rejection
(p= 0.043). Patients without early complications (rejection or
infection) had a mean hospital stay of 12 days after OLT. A
higher MELD score was observed in patients with infection
(27.14¡6.05) compared with those without infection.
Comparison groups - early complication
The mean dose of Tacrolimus was lower on the third day
after transplantation in both groups with early complications
(infection and rejection), marking a statistically significant
level of difference (p,0.05). However, when the blood level
Table 1 - Demographic parameters for all liver transplantation patients.
Parameter Liver Transplantation (n= 44)
Sex (n/%) M= 30 (68.18%)/F = 14 (31.82%)
Mean age (years) 52.43 (¡12.33)
Median age (years) 55.5 (range, 19-71)
Mean hospital stay (days) 16.1¡9.32
MELD score 26.18¡4.28
Cause of transplantation HCV cirrhosis (47.7%) alcoholic cirrhosis (13.6%) primary sclerosing cholangitis
(6.8%) cryptogenic cirrhosis (6.8%) autoimmune hepatitis (6.8%) hepatitis B
virus cirrhosis (6.8%) nonalcoholic fatty liver disease (4.7%) other (6.8%)
Mean body max index 25.94¡4.58
Acute cellular rejection (ACR) n=5 (11.37%)
ACR without infection n=3 (6.82%)
Infection n=16 (36.37%)
Infection without ACR n=14 (31.82%)
Abbreviations: ACR: acute cellular rejection, GFR: glomerular filtration rate; Creat: creatinine; Tacrolimus dose (mg/kg/day), serum level of Tacrolimus (ng/
ml) and days after transplant (t).
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of Tacrolimus was higher than 10 ng/ml in the infection
group (11.38 ng/ml), a decrease in GFR (p= 0.048) on day 15
after OLT (Table 2) was observed.
Infection x No infection
Differences in the mean dose of Tacrolimus over time
were found between the groups with and without infection
(p,0.001), as shown in Figure 1A. The mean dose was
increased until day 7 and was subsequently reduced.
There were differences in the mean blood level of
Tacrolimus over time in both groups (p,0.001), as shown
in Figure 1B. We observed a constant increase in the level of
Tacrolimus in the group with infection, which differed from
the group without infection on day 10 after LT.
Rejection x No rejection
There were differences in the mean dose of Tacrolimus
over time between these groups (p= 0.0314, Figure 1C). An
increase in the Tacrolimus dose was followed by a reduction
after the seventh day in the group without rejection and
after the tenth day for the group with rejection.
There were differences in the mean level of Tacrolimus
over time between the groups (p= 0.0314, Figure 1D).
Notably, there was an increase in the level of Tacrolimus
in the rejection group after the tenth day.
Differences between the mean GFR for the groups with and
without rejection were observed over all time points (p= 0.0084).
We observed a significant decrease in GFR when the blood level
of Tacrolimus increased to more than 10 ng/ml (Figure 1F) or
the dose increased to greater than 0.15 mg/kg/day (Figure 1E).
This decrease was followed by an improvement in GFR after the
reduction of both the Tacrolimus dose and level.
& DISCUSSION
An analysis of the graphics over time shows a significant
correlation between the serum or dose level of Tacrolimus
and the deterioration of the GFR and serum creatinine.
Rodrı´guez-Pera´lvarez et al. (10) performed a systematic
review and meta-analysis on this topic. Their aim was to
determine how lower than currently recommended Tacrolimus
concentrations affect acute rejection rates and renal impairment.
Among randomized trials, the mean Tacrolimus trough
concentration during the first month positively correlates with
renal impairment within 1 year post-transplant. A meta-
analysis of randomized trials directly comparing Tacrolimus
trough concentrations showed that "reduced Tacrolimus’’
levels (,10 ng/ml) within the first month after liver transplan-
tation were associated with less renal impairment at 1 year (10).
In this study, we observed a significant correlation between
Tacrolimus blood level and decreased GFR.
The curve of the Tacrolimus level versus GFR showed an
increase until the fifteenth day, followed by a brief drop until the
twenty-fifth day and, finally, a sudden rise on the thirtieth day.
This late rise may be due to the small number of individuals
assessed on the last day of the study. This Tacrolimus curve is
similar to the dose versus GFR curve. There was an increase in
the mean dose until the seventh day, which, when considering
the measurement delay, likely corresponds to the increase in
GFR observed until the tenth day post-LT. This increase was
followed by reductions in both curves.
Kong et al. (4) showed that, in a CNI minimization group
(lower CNI dose than in a routine CNI regimen group),
creatinine levels were significantly decreased. However,
creatinine clearance was not significantly higher in the CNI
minimization group. Both acute rejection episodes and
patient survival were comparable between the groups.
Therefore, the current CNI minimization protocols may be
accompanied by a greater number of infections (4). Lower
trough concentrations of Tacrolimus (6-10 ng/ml during the
first month) would be more appropriate after OLT (10). In
our study, we observed that patients with Tacrolimus levels
up to 10 ng/ml had fewer early complications.
Despite the recommendations, in this study, we observed
that a decreased serum level of Tacrolimus was better at
preventing infection and acute cellular rejection. However,














Age 53.93¡9.71 52.52¡13.62 NA 42.67¡15.53 52.52¡13.62 0.352
Weight 72.57¡26.39 75.44¡12.99 0.151 82.17¡18.94 75.44¡12.99 0.602
H. stay 22.21¡12.95 12.28¡4.2 0.003 18¡4.36 12.28¡4.2 0.043
MELD 27.14¡6.05 25.44¡3.2 0.806 25.67¡2.89 25.44¡3.2 NA
Dose.t3 0.55¡0.33 0.068¡0.32 0.044 0.066¡0.33 0.06¡0.32 0.048
Dose.t5 0.096¡0.30 0.130¡0.31 0.057 0.066¡0.33 0.067¡0.32 0.824
Dose.t7 0.174¡0.31 0.117¡0.32 0.044 0.198¡0.39 0.147¡0.32 0.960
Dose.t10 0.107¡0.41 0.187¡0.44 0.266 0.188¡0.53 0.149¡0.38 0.261
Dose.t15 0.089¡0.48 0.117¡0.58 0.421 0.129¡0.70 0.097¡0.52 0.857
Level.t3 3.62¡3.47 3.76¡1.98 0.452 8.00¡5.80 3.76¡1.98 0.231
Level.t5 4.23¡2.42 5.4¡2.47 0.192 7.37¡5.04 5.4¡2.47 0.630
Level.t7 6.21¡4.56 7.94¡3.25 0.068 9.20¡2.74 7.94¡3.25 0.470
Level.t10 8.41¡5.86 9.67¡3.61 0.140 15.43¡10.67 9.67¡3.61 0.396
Level.t15 11.31¡3.8 7.6¡3.140 0.012 12.37¡2.63 7.6¡3.14 0.030
GFR.t3 59.95¡25.71 82.93¡42.56 0.105 110.2¡8.52 82.93¡42.56 0.125
GFR.t5 67.79¡41.22 80.53¡39.95 0.176 88.23¡5.06 80.53¡39.95 0.353
GFR.t7 71.96¡36.21 84.03¡54.19 0.314 95.23¡27.25 84.03¡54.19 0.219
GFR.t10 75.39¡49.22 88.21¡53.84 0.416 103.53¡29.44 88.21¡53.84 0.351
GFRt15 58.96¡29.33 83.29¡34.47 0.048 102.63¡14.48 83.29¡34.47 0.248
Note: Mean and standard deviations (SD).
Abbreviations: MELD: Model for End-Stage Liver Disease; ACR: acute cellular rejection; GFR: glomerular filtration rate (ml/min); Creat: creatinine (mg/dl);
H. stay: hospital stay; Tacrolimus dose (mg/kg/day), serum level of Tacrolimus (ng/ml) and days after transplant (t).
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Figure 1 - Comparisons of different parameters after liver transplantation. A - Tacrolimus dose and infection rate over 15 days. B -
Serum level of Tacrolimus and infection rate over 15 days. C - Tacrolimus dose and acute cellular rejection rate over 15 days. D - Serum
level of Tacrolimus and acute cellular rejection over 15 days. E - Tacrolimus dose and glomerular filtration rate over 30 days. F - Serum
level of Tacrolimus and glomerular filtration rate over 30 days.
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we only evaluated nephrotoxicity and did not examine
neurotoxicity or diabetes mellitus as additional endpoints.
Other studies have shown that (11) a Tacrolimus concentra-
tion of 5 to ,8 ng/ml is associated with the least overall
toxicity, neurotoxicity and ACR. The neurotoxicity was
lowest in the trough range from 5 to ,8 ng/ml and diabetes
mellitus was present in 11% to 18% of patients across the
various trough ranges, including the extremes (mean trough
level, 8.4¡4.4 ng/dl) (11).
In conclusion, when the average Tacrolimus serum level
was above 10 ng/ml and the dose was greater than
0.15 mg/kg/day acute cellular rejection was prevented;
however, this dose was also associated with reduced renal
function and, occasionally, infectious disease.
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